A group of investors including Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Metaplanet, Puhua Capital and Tencent, led a $103m Series B round in bit.bio, a biotechnology company in England. "I’m thrilled that bit.bio is supported by world class investors and strategic partners. The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere," Mark Kotter, bit.bio CEO.